Metastatic pancreatic poorly differentiated neuroendocrine carcinoma: current treatment considerations.
نویسنده
چکیده
Pancreatic poorly differentiated neuroendocrine tumors (PDNETs) are a subtype of neuroendocrine tumors (NETs) that are clinically distinguished by their very rapid growth. They are immunohistochemically diagnosed by having a higher Ki-67 cancer cell staining percentage when compared with well or intermediately differentiated NETs. These tumors are typically treated in the same manner as small cell lung cancer. Recent advances in the treatment of well or intermediately differentiated NETs have raised the question of whether such therapies may also have efficacy in PDNETs.
منابع مشابه
Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas.
Poorly differentiated neuroendocrine carcinoma is a rare malignancy that remains a challenge to treat. Poorly differentiated neuroendocrine carcinoma occurs at an incidence of 2% annually in United States. The current standard of care is based largely upon retrospective data. There remains a need for large prospective cooperative group trials in the management of poorly differentiated neuroendo...
متن کاملProlonged Radiographic Stabilization of a Metastatic Octreotide Scan-Positive Poorly Differentiated Neuroendocrine Tumor Using Octreotide Acetate Therapy Alone
Pancreatic poorly differentiated neuroendocrine tumors (PDNETs) are a subtype of neuroendocrine Tumors (NETs) clinically distinguished by their much more rapid growth and immunohistochemically diagnosed by having a higher Ki-67 cancer cell staining percentage compared to their well or intermediately differentiated NET counterparts. While standard first line treatment for metastatic well or inte...
متن کاملGemcitabine as salvage treatment in patients with poorly differentiated pancreatic neuroendocrine tumors: a case series.
CONTEXT Poorly differentiated neuroendocrine carcinoma of the pancreas is a rare and aggressive tumor. The combination of etoposide and cisplatin is considered as the first-line treatment, but no recommendations exist for further treatment after progression. CASE SERIES We report here case series of three patients who received gemcitabine as salvage chemotherapy in patients with poorly differ...
متن کاملThe prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy
RATIONALE Pancreatic neuroendocrine tumors (pNET) are rare slowly growing tumors with a high metastatic potential. Peptide receptor radionuclide therapy (PRRT) with radiolabeled analogues has been developed as a new tool for the management of metastatic well-differentiated (grade 1 and 2) neuroendocrine tumors expressing somatostatin receptor (SSTR2). Chemotherapy is the mainstay in the managem...
متن کاملBreast metastasis from the pancreatic neuroendocrine tumor origin detected by 99mTc-Octreotate scan
A 50 years old woman with history of pancreatic neuroendocrine tumor diagnosed 2 years ago, which has not been surgically removed,was referred to our department for a 99mTc-Octreotate in order to evaluate the somatostatin receptor status. She was treated with regular sandostatin injections and chemotherapy. Her CT scan which was previously performed confirmed lung, adrenal and hepati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Clinical advances in hematology & oncology : H&O
دوره 11 12 شماره
صفحات -
تاریخ انتشار 2013